Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 1997

View Archived Issues

Hoechst Marion Roussel's product pipeline in review

Novel progestins described by Gedeon Richter

New compounds from Knoll for CNS disorders

Pfizer describes agents for dopamine system disorders

Acetylcholinesterase inhibitors under development at Astra

Abbott searches for squalene synthase inhibitors as hypolipidemics

New SERMs prepared at Lilly

Axokine use in retinal degeneration covered in new patent

BM-41.0904: a potential new osteoanabolic agent

New levobupivacaine clinical data presented at European congress

Genetronics receives Phase I SBIR grant for heparin delivery

Orapex: new dental company formed in Canada

First launch for Zeneca's Seroquel

Celgene's thalidomide approvable for ENL

Geron, Johns Hopkins collaborate on stem cell research

Octreotide acetate clinical study commences for new indication

Clinical trials begin with topical impotence treatment

Orphan Medical licenses out European rights to Antizol

Columbia Laboratories issued U.S. patent for drug delivery technology

Cardizem Monovial approved for U.S. marketing

Amgen seeks partner for inflammation R&D program

Cytoclonal allowed U.S. patent for PKD treatment

Acute vasodilating effects of KDI-792 in diabetics

NABI introduces new formulation of WinRho SDF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...